Questions Answered in This Report:
- What are the treatment drivers and goals for moderate to severe CD?
- What attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for moderate to severe CD?
- What are the prevailing areas of unmet need and opportunity in moderate to severe CD?
- What trade-offs across different clinical attributes and price are acceptable to and European gastroenterologists for a hypothetical new moderate to severe CD drug?
The treatment of moderate to severe Crohn’s disease ( CD ) presents an attractive commercial opportunity for new, effective therapies. Despite the revolution that TNF -α inhibitors (, Janssen/Merck’s Remicade, AbbVie/Eisai’s Humira) brought to the market, safety risks and efficacy limitations associated with these therapies still exist. In the past two years, the CD market has welcomed two new agents─Takeda’s Entyvio (approved in 2014) and Janssen’s Stelara (approved in 2016)─that offer different mechanisms of action ( MOA s) from the TNF -α inhibitors. The launch of these novel agents has helped address some unmet need, but significant needs persist, especially for patients refractory to available therapies.
Markets covered: United States, France, Germany, United Kingdom.
Primary research: Survey of 62 and 30 European gastroenterologists fielded in May 2017.
Key companies: AbbVie, Biogen, Celltrion, Eisai, Johnson & Johnson, Pfizer, Merck & Co, Takeda, UCB.
Key drugs: Azathioprine, Cimzia, cx-601, Entyvio, etrolizumab, filgotinib, Inflectra/Remsima/Flixabi, Humira, mongersen, Remicade, Stelara.